ErbB3 binding protein compositions and methods of use
View Patent ↗A method of repressing a cell-cycle gene, which is regulated by an E2F transcription factor, in a cell, wherein the method comprises contacting the cell with a cell-cycle gene-repressing amount of ErbB3 binding protein (Ebp1); a method of inhibiting prostate cancer in a mammal, wherein the method comprises administering to the mammal a prostate cancer-inhibiting amount of Ebp1; a composition comprising an Ebp1-expressing viral vector that expresses a cell-cycle gene-repressing amount of Ebp1; and a composition comprising polymer-packaged DNA comprising and expressing a cell-cycle gene-repressing amount of Ebp1.
1. A method of repressing a cell-cycle gene, which is regulated by a level of an E2F transcription factor, in a cell in a tumor in a mammal, which method comprises contacting the cell in the tumor in the mammal with a nucleic acid encoding Ebp1 protein which expresses in the cell in the tumor in the mammal a cell-cycle gene repressing amount of Ebp1 protein, whereupon the cell-cycle gene is repressed.
2. The method of claim 1 , wherein the Ebp1 protein is expressed from a viral vector, in which case the cell is contacted with the viral vector.
3. The method of claim 2 , wherein the viral vector is a lentiviral vector.
4. The method of claim 2 , wherein the viral vector is targeted to a cell-surface molecule.
5. The method of claim 2 , wherein the viral vector is injected into or in the immediate vicinity of the tumor.
6. The method of claim 1 , wherein the Ebp1 protein is expressed from polymer-packaged DNA, in which case the cell is contacted with the polymer-packaged DNA.
7. The method of claim 1 , wherein the Ebp1 protein is overexpressed.
8. The method of claim 1 , wherein the nucleic acid encoding Ebp1 protein is set forth in SEQ ID NO: 1.
9. A method of suppressing or slowing the growth of prostate cancer in a mammal, which method comprises administering to the mammal a nucleic acid encoding Ebp1 protein, wherein Ebp1 protein is expressed in the prostate cancer in the mammal, whereupon growth of the prostate cancer in the mammal is suppressed or slowed.
10. The method of claim 9 , wherein the Ebp1 protein is expressed from a viral vector, in which case the prostate cancer is contacted with the viral vector.
11. The method of claim 10 , wherein the viral vector is a lentiviral vector.
12. The method of claim 10 , wherein the viral vector is targeted to a cell-surface molecule.
13. The method of claim 10 , wherein the viral vector is injected into or in the immediate vicinity of a tumor in the prostate.
14. The method of claim 9 , wherein the Ebp1 protein is expressed from polymer-packaged DNA, in which case the cell is contacted with the polymer-packaged DNA.
15. The method of claim 9 , wherein the Ebp1 protein is overexpressed.
16. The method of claim 9 , wherein the nucleic acid encoding Ebp1 protein is set forth in SEQ ID NO: 1.
17. A method of treating prostate cancer in a mammal, which method comprises administering to the mammal a nucleic acid encoding Ebp1 protein, wherein Ebp1 protein is expressed in the prostate cancer in the mammal, whereupon the prostate cancer in the mammal is treated.
18. The method of claim 17 , wherein the Ebp1 protein is expressed from a viral vector, in which case the prostate cancer is contacted with the viral vector.
19. The method of claim 18 , wherein the viral vector is a lentiviral vector.
20. The method of claim 18 , wherein the viral vector is targeted to a cell-surface molecule.
21. The method of claim 18 , wherein the viral vector is injected into or in the immediate vicinity of a tumor in the prostate.
22. The method of claim 17 , wherein the Ebp1 protein is expressed from polymer-packaged DNA, in which case the prostate cancer is contacted with the polymer-packaged DNA.
23. The method of claim 17 , wherein the Ebp1 protein is overexpressed.
24. The method of claim 17 , wherein the nucleic acid encoding Ebp1 protein is set forth in SEQ ID NO: 1.